116 related articles for article (PubMed ID: 20400411)
1. Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.
Yeh TM; Evans SR; Gulick RM; Clifford DB
HIV Clin Trials; 2010; 11(1):51-8. PubMed ID: 20400411
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
[TBL] [Abstract][Full Text] [Related]
3. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
Caseiro MM; Nelson M; Diaz RS; Gathe J; de Andrade Neto JL; Slim J; Solano A; Netto EM; Mak C; Shen J; Greaves W; Dunkle LM; Vilchez RA; Zeinecker J
J Infect; 2012 Oct; 65(4):326-35. PubMed ID: 22634184
[TBL] [Abstract][Full Text] [Related]
4. Peripheral neuropathy in HIV: prevalence and risk factors.
Evans SR; Ellis RJ; Chen H; Yeh TM; Lee AJ; Schifitto G; Wu K; Bosch RJ; McArthur JC; Simpson DM; Clifford DB
AIDS; 2011 Apr; 25(7):919-28. PubMed ID: 21330902
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR;
J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).
Crawford KW; Li C; Keung A; Su Z; Hughes MD; Greaves W; Kuritzkes D; Gulick R; Flexner C;
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):598-605. PubMed ID: 20071999
[TBL] [Abstract][Full Text] [Related]
7. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
[TBL] [Abstract][Full Text] [Related]
8. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
Suleiman J; Zingman BS; Diaz RS; Madruga JV; DeJesus E; Slim J; Mak C; Lee E; McCarthy MC; Dunkle LM; Walmsley S
J Infect Dis; 2010 Feb; 201(4):590-9. PubMed ID: 20064072
[TBL] [Abstract][Full Text] [Related]
9. Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.
Fätkenheuer G; Hoffmann C; Slim J; Rouzier R; Keung A; Li J; Treitel M; Sansone-Parsons A; Kasserra C; O'Mara E; Schürmann D
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):78-85. PubMed ID: 19838130
[TBL] [Abstract][Full Text] [Related]
10. Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
O'Mara E; Kasserra C; Huddlestone JR; Wan Y; Soni P; Caceres M; Medlock M; Morrison R; Devinsky O
Antimicrob Agents Chemother; 2010 Jun; 54(6):2448-54. PubMed ID: 20350942
[TBL] [Abstract][Full Text] [Related]
11. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
McNicholas PM; Mann PA; Wojcik L; Qiu P; Lee E; McCarthy M; Shen J; Black TA; Strizki JM
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):222-9. PubMed ID: 21209592
[TBL] [Abstract][Full Text] [Related]
12. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
Heredia A; Latinovic O; Gallo RC; Melikyan G; Reitz M; Le N; Redfield RR
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20476-81. PubMed ID: 19075241
[TBL] [Abstract][Full Text] [Related]
13. Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.
Chen H; Clifford DB; Deng L; Wu K; Lee AJ; Bosch RJ; Riddler SA; Ellis RJ; Evans SR
J Neurovirol; 2013 Dec; 19(6):557-64. PubMed ID: 24297499
[TBL] [Abstract][Full Text] [Related]
14. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
Wilkin TJ; Su Z; Krambrink A; Long J; Greaves W; Gross R; Hughes MD; Flexner C; Skolnik PR; Coakley E; Godfrey C; Hirsch M; Kuritzkes DR; Gulick RM
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):470-6. PubMed ID: 20672447
[TBL] [Abstract][Full Text] [Related]
15. Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.
Wang SX; Ho EL; Grill M; Lee E; Peterson J; Robertson K; Fuchs D; Sinclair E; Price RW; Spudich S
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):303-10. PubMed ID: 24732871
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.
Liu AY; Zhang J; Anderson PL; Wagner T; Pan Z; Peda M; Gomez K; Beamer M; Jacobson C; Strizki J; Dezzutti CS; Piper JM;
Clin Infect Dis; 2019 Mar; 68(7):1129-1135. PubMed ID: 30289444
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy.
Dinat N; Marinda E; Moch S; Rice AS; Kamerman PR
PLoS One; 2015; 10(5):e0126297. PubMed ID: 25974287
[TBL] [Abstract][Full Text] [Related]
19. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra C; Li J; March B; O'Mara E
Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.
Hoesley CJ; Chen BA; Anderson PL; Dezzutti CS; Strizki J; Sprinkle C; Heard F; Bauermeister J; Hall W; Jacobson C; Berthiaume J; Mayo A; Gundacker H; Richardson-Harman N; Piper J;
Clin Infect Dis; 2019 Mar; 68(7):1136-1143. PubMed ID: 30289435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
